Intended for healthcare professionals

Latest dermatology news

 

UCB announces two-year data for Bimzelx in hidradenitis suppurativa

The results showed that improvements observed with the drug were maintained at week 96

03 Oct 2024

Sanofi/Regeneron’s Dupixent shows promise in phase 3 chronic spontaneous urticaria study

The inflammatory skin disease affects approximately 40 million people globally

27 Sep 2024

Merck announces ten-year data for anti-PD-1 therapy Keytruda in melanoma

Over 100,640 people are expected to be diagnosed with melanoma in the US this year

27 Sep 2024

Eli Lilly receives FDA approval for IL-13 inhibitor Ebglyss in atopic dermatitis

Approximately 40% of atopic dermatitis patients have moderate or severe symptoms

19 Sep 2024

Acelyrin’s izokibep shows promise in phase 3 hidradenitis suppurativa trial

The chronic inflammatory skin condition is estimated to affect about 1% of the population in most studied countries

12 Sep 2024

BioNTech’s mRNA immunotherapy candidate shows promise in advanced melanoma

BNT111 in combination with Libtayo previously received fast track designation from the US Food and Drug Administration

06 Sep 2024

FDA approves Galderma’s monoclonal antibody Nemluvio to treat prurigo nodularis

The regulator is also reviewing the IL-31 inhibitor as a treatment for atopic dermatitis

29 Aug 2024

Almirall receives NICE recommendation for Ebglyss in moderate-to-severe atopic dermatitis

The IL-13 inhibitor can now be used to treat adults and adolescents who are candidates for systemic therapy

22 Aug 2024

Boehringer receives positive CHMP opinion for Spevigo in generalised pustular psoriasis

The inflammatory disease can lead to complications including multisystem organ failure and sepsis
 

08 Aug 2024

FDA approves Sun Pharma’s Leqselvi to treat severe alopecia areata in adults

The oral JAK inhibitor is designed to interrupt the pathways that are thought to contribute to hair loss

01 Aug 2024
12345678910...